Modified porous tantalum rod technique for the treatment of femoral head osteonecrosis

Pakos, Emilios E.; Megas, Panayiotis; Paschos, Nikolaos K.; Syggelos, Spyridon A; Kouzelis, Antonis; Georgiadis, Georgios; Xenakis, Theodoros

doi:10.5312/wjo.v6.i10.829

Cited by 27 publications

(20 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ideally, ONFH should be treated early. Before femoral head collapse, many therapeutic methods are available, including but not limited to high-pressure oxygen, 31 extracorporeal shock wave therapy, 32 core decompression, 33 and tantalum rod implantation 34 . However, no single method has shown complete success in preventing collapse.…”

Section: Discussionmentioning

confidence: 99%

AAV-Anti-miR-214 Prevents Collapse of the Femoral Head in Osteonecrosis by Regulating Osteoblast and Osteoclast Activities

Wang

Sun

Ling

et al. 2019

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

Osteonecrosis of the femoral head, an intractable but common disease that eventually triggers collapse of the femoral head, is characterized by increased osteoclast activity and markedly decreased osteoblast activity in the necrotic region of the femoral head. MicroRNA (miRNA)-214 (miR-214) may play important roles in vertebrate skeletal development by inhibiting osteoblast function by targeting activating transcription factor 4 (ATF4) and promoting osteoclast function via phosphatase and tensin homolog (PTEN). This study revealed significantly increased levels of miR-214 in necrotic regions, with commensurate changes in the numbers of its target cells (both osteoblasts and osteoclasts). To investigate whether targeting miR-214 could prevent femoral head collapse, we constructed an adeno-associated virus (AAV)-associated anti-miR-214 (AAV-anti-miR-214) and evaluated its function in vivo. AAV-anti-miR-214 promoted osteoblast activity and diminished osteoclast activity, effectively preventing collapse of the femoral head in a rat model of osteonecrosis.

show abstract

Section: Discussionmentioning

confidence: 99%

AAV-Anti-miR-214 Prevents Collapse of the Femoral Head in Osteonecrosis by Regulating Osteoblast and Osteoclast Activities

Wang

Sun

Ling

et al. 2019

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

show abstract

“…However, there was a shorter operation time with less blood loss. 67 In a meta-analysis by Zhang et al, the authors made a pooling of six studies and could conclude that was a significantly improved HHS compared with non-vascularized bone grafts. There also appears to be an improvement in the survival rates.…”

Section: Novel Strategiesmentioning

confidence: 99%

Osteonecrosis of the femoral head: pathophysiology and current concepts of treatment

2019

View full text Add to dashboard Cite

Osteonecrosis of the femoral head is a disabling pathology affecting a young population (average age at treatment, 33 to 38 years) and is the most important cause of total hip arthroplasty in this population. It reflects the endpoint of various disease processes that result in a decrease of the femoral head blood flow. The physiopathology reflects an alteration of the vascularization of the fine blood vessels irrigating the anterior and superior part of the femoral head. This zone of necrosis is the source of the loss of joint congruence that leads to premature wear of the hip. Several different types of medication have been developed to reverse the process of ischemia and/or restore the vascularization of the femoral head. There is no consensus yet on a particular treatment. The surgical treatments aim to preserve the joint as far as the diagnosis could be made before the appearance of a zone of necrosis and the loss of joint congruence. They consist of bone marrow decompressions, osteotomies around the hip, vascular or non-vascular grafts. Future therapies include the use of biologically active molecules as well as implants impregnated with biologically active tissue. Cite this article: EFORT Open Rev 2019;4:85-97. DOI: 10.1302/2058-5241.4.180036

show abstract

“…Another group of the researcher used tantalum rods in an advanced stage of stage 2 and 3 of FHN, in combination with bone marrow and autologous bone grafts. After 5 y of treatment only 3 and 15 % of cases in stages II and III, respectively were further shifted to total hip replacement [61][62][63] .…”

Section: Femoral Head Osteonecrosis Treatment By Using Biomaterialsmentioning

confidence: 99%

Bone Regeneration Therapy of Atraumatic Necrosis of Femoral Head

Zhao¹

2020

pharmaceutical-sciences

View full text Add to dashboard Cite

Zhao et al.: Bone regeneration therapy of femoral head Femoral head necrosis is a mobility disorder and till now no satisfactory solution has been reported. The principal contributing factor in the pathogenesis of the disease is insufficient blood supply to the femoral head resulting in necrosis of the femoral head. Various preventive measures required to treat femoral head necrosis include revascularization, adequate supply of osteogenic cells and establishing enough strength to avoid collapse. Among all, cell transplantation therapy is considered the most favourable treatment strategy for femoral head necrosis. However, the results merely depend on the etiology and the clinical stage of femoral head necrosis. Thus, it is better to make a treatment plan according to the epidemiology, disease status and stage. The main objective of this communication is to study the treatment of femoral head necrosis with cell replacement therapy and also its effects by focusing on the disease stages.

show abstract

Modified porous tantalum rod technique for the treatment of femoral head osteonecrosis

Abstract: The modified porous tantalum rod technique presented here showed encouraging outcomes. The survival rates based on conversion to THA are the lowest reported in the published literature.

Cited by 27 publications

References 35 publications

AAV-Anti-miR-214 Prevents Collapse of the Femoral Head in Osteonecrosis by Regulating Osteoblast and Osteoclast Activities

AAV-Anti-miR-214 Prevents Collapse of the Femoral Head in Osteonecrosis by Regulating Osteoblast and Osteoclast Activities

Osteonecrosis of the femoral head: pathophysiology and current concepts of treatment

Bone Regeneration Therapy of Atraumatic Necrosis of Femoral Head

Contact Info

Product

Resources

About